Regulation of Cholesterol and Fatty Acid Synthesis

Jin Ye and Russell A. DeBose-Boyd

Cold Spring Harb Perspect Biol 2011;3:a004754 originally published online April 6, 2011

References

This article cites 59 articles, 34 of which can be accessed free
http://cshperspectives.cshlp.org/content/3/7/a004754.full.html#ref-list-1

Article cited in:
http://cshperspectives.cshlp.org/content/3/7/a004754.full.html#related-urls

Email alerting service

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or click here

Subject collection

Articles on similar topics can be found in the following collection

The Biology of Lipids (20 articles)
Regulation of Cholesterol and Fatty Acid Synthesis

Jin Ye and Russell A. DeBose-Boyd

1Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, Texas 75390
2Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, Texas 75390

Correspondence: russell.debose-boyd@utsouthwestern.edu

In mammals, intracellular levels of cholesterol and fatty acids are controlled through a feedback regulatory system mediated by a family of transcription factors called sterol regulatory element-binding proteins (SREBPs). SREBPs are synthesized as inactive precursors bound to membranes of the endoplasmic reticulum. When cells are deprived of cholesterol and fatty acids, NH2-terminal fragments of SREBPs become proteolytically released from membranes and migrate to the nucleus to activate transcription of genes required for lipid synthesis and uptake. Conversely, lipid repletion inhibits proteolytic processing of SREBPs and thereby suppresses lipid accumulation. We review here studies in cultured cells that reveal the mechanism for regulation of SREBP proteolytic activation, and those in animal models in which SREBP proteolysis has been either activated or inhibited to show the essential role of SREBPs in regulating hepatic lipid homeostasis.

REGULATION OF CHOLESTEROL AND FATTY ACID SYNTHESIS

Cholesterol and fatty acids are important building blocks for animal cell membranes and their synthesis is essential for life. However, overproduction of cholesterol and fatty acids can be toxic to cells as well as to the whole animal, which evokes the need for regulatory mechanisms that control intracellular levels of these lipids. This homeostatic control is achieved by a feedback regulatory system that senses intracellular levels of cholesterol and fatty acids and modulates transcription of genes encoding lipogenic enzymes. The modulators are a family of membrane-bound transcription factors called sterol regulatory element-binding proteins (SREBPs) (Brown and Goldstein 1997). Mammalian cells produce three isoforms of SREBPs. SREBP-1a and SREBP-1c are produced from a single gene using alternate promoters that produce transcripts with a different first exon, whereas SREBP-2 is encoded by a separate gene (Hua et al. 1995). Unlike typical transcription factors, SREBPs are synthesized as integral membrane proteins localized in the endoplasmic reticulum (ER). The NH2-terminal and the COOH-terminal domains of the proteins project into the cytosol (Fig. 1). They are anchored to membranes by a central domain containing two membrane-spanning sequences separated by a short loop that projects into the
The NH₂-terminal domains of SREBPs are transcription factors of the basic-loop-helix-leucine zipper family that bind to enhancer sequences located in the promoters of lipogenic genes to activate transcription (Smith et al. 1990; Horton et al. 2003). These enhancer sequences are known as sterol response elements or SREs. Among the three isoforms of SREBPs, the NH₂-terminal domains of SREBP-1a and SREBP-1c are more active in driving transcription of genes involved in fatty acid synthesis, whereas that of SREBP-2 is more active in stimulating transcription of genes involved in cholesterol biosynthesis (Pai et al. 1998; Horton et al. 2003). However, in order for the NH₂-terminal domains of SREBPs to activate transcription in the nucleus, they have to be first released from the membrane. The proteolytic pathway that liberates the NH₂-terminal fragment of SREBPs from membranes in response to intracellular levels of cholesterol and fatty acids is known as the SREBP pathway (Brown and Goldstein 1997).

Figure 1. The SREBP pathway. When cells are depleted of sterols and fatty acids, SREBPs are transported from the ER to the Golgi apparatus, in which they are first cleaved by the Golgi-localized Site-1 Protease (S1P). S1P cleaves SREBPs in the luminal loop between the two membrane-spanning sequences. Once the two halves of the SREBP are separated, a second Golgi protease, Site-2 Protease (S2P), cleaves the NH₂-terminal bHLH-Zip domain of SREBPs at a site located three residues within the membrane-spanning region. After the second cleavage, the NH₂-terminal domain is released from the membrane and enters the nucleus, in which it activates genes controlling lipid synthesis.

REGULATION OF THE SREBP PATHWAY IN CULTURED CELLS

Regulated Intramembrane Proteolysis of SREBPs

In cells that are depleted of cholesterol, the NH₂-terminal domains of SREBPs are released from membranes by two sequential proteolytic cleavages. The first proteolytic reaction cleaves the SREBPs at a site within the lumen of the ER (Fig. 1). Once the two halves of the SREBP are separated, a second Golgi protease, Site-2 Protease (S2P), cleaves the NH₂-terminal bHLH-Zip domain of SREBPs at a site located three residues within the membrane-spanning region. After the second cleavage, the NH₂-terminal domain is released from the membrane and enters the nucleus, in which it activates genes controlling lipid synthesis.
is buried within the membrane (Fig. 1) (Rawson et al. 1997; Feng et al. 2007). Site-2 cleavage releases the NH₂-terminal domains of the SREBPfs from membranes, allowing them to enter the nucleus and activate transcription of their target genes (Fig. 1). S2P cleaves SREBP-2 at a site that is three residues within the putative transmembrane segment (Duncan et al. 1998). This cleavage does not occur until the bulk of the luminal portion of SREBPfs is first removed by S1P-mediated proteolysis (Sakai et al. 1996). Cleavage by S2P also requires helix-breaking residues distal to the cleavage site in the transmembrane domain (Ye et al. 2000). These residues may partially unwind the α-helical structure surrounding the cleavage site so that the scissile peptide bond is accessible to the protease.

Proteolytic activation of SREBPfs is the first example of a signal transduction pathway that involves the generation of regulatory molecules from membrane proteins through proteolytic cleavage. In addition to lipid metabolism, this signaling mechanism, which is termed Regulated Intramembrane Proteolysis (RIP), influences processes as diverse as cellular differentiation, immune defense and the response to unfolded proteins (Brown et al. 2000).

Sterols and fatty acids inhibit RIP of SREBPfs by separating SREBPfs from S1P and S2P. S1P and S2P are active in the Golgi complex, whereas SREBPfs are localized in the ER of lipid-loaded cells (Fig. 1) (DeBose-Boyd et al. 1999). Following lipid-depletion, SREBPfs are transported from the ER to the Golgi complex in which they encounter active S1P and S2P (DeBose-Boyd et al. 1999; Nohturfft et al. 2000). This lipid-regulated, ER to Golgi transport of SREBPfs is controlled by a pair of polytopic ER membrane proteins: Scap and Insig.

Sterols Control RIP of SREBPfs by Two Intracellular Sterol Sensors: Scap and Insig

Scap is a polytopic membrane protein that contains an NH₂-terminal domain with eight transmembrane helices and a cytosolic COOH-terminal domain that mediates complex formation with the COOH-terminal domain of SREBPfs (Fig. 2) (Sakai et al. 1997). In sterol-depleted cells, the Scap/SREBP complex exits the ER in COPII-coated vesicles that bud from ER membranes (Fig. 2) (Nohturfft et al. 2000; Espenshade et al. 2002; Sun et al. 2005). As a result, SREBPfs are cleaved by S1P and S2P in the Golgi complex and the transcription factor domain is released from membranes. When cholesterol builds up in ER membranes, the sterol binds to Scap (Radhakrishnan et al. 2004), and this triggers a conformational change in its cytosolic loop located between TM helices six and seven (Fig. 2) (Brown et al. 2002; Sun et al. 2005). This conformational change causes Scap to bind Insig proteins, which disrupts the interaction of Scap with components of the COP-II coat and results in the retention of the Scap/SREBP complex in the ER (Sun et al. 2005). Scap responds cooperatively to ER cholesterol levels to control SREBP activation in a switch-like manner so that SREBP-2 transport is abruptly blocked when ER cholesterol exceeds 5% of total ER lipids (molar basis) (Radhakrishnan et al. 2008).

Mammalian cells contain two isoforms of Insig proteins, namely Insig-1 and Insig-2 (Yabe et al. 2002; Yang et al. 2002). Both proteins are polytopic membrane proteins with six transmembrane helices (Feramisco et al. 2004) that bind to cholesterol-loaded Scap to retain the Scap/SREBP complex in the ER (Yabe et al. 2002; Yang et al. 2002). Insig proteins also play an important role in oxysterol-regulated cleavage of SREBPfs. In addition to cholesterol, oxysterols such as 25-hydroxycholesterol potently inhibit cleavage of SREBPfs (Hua et al. 1996a). However, this oxysterol does not bind Scap, nor does it induce the conformational change in Scap (Adams et al. 2004; Radhakrishnan et al. 2004). Instead, 25-hydroxycholesterol binds to purified recombinant Insig proteins (Radhakrishnan et al. 2007). Remarkably, Insigs do not bind to cholesterol. These observations suggest that 25-hydroxycholesterol and cholesterol trigger Scap-Insig through distinct mechanisms: 25-hydroxycholesterol binds to the Insig proteins, whereas cholesterol binds to Scap. Both of these binding reactions produce the same result: ER retention of the Scap/SREBP complex.
In addition to retaining the Scap/SREBP complex in the ER, Scap-Insig binding modulates degradation of Insig-1 protein. In sterol-replete cells, Insig-1 binds to Scap and becomes rapidly ubiquitinated and degraded by proteasomes (Fig. 2). This degradation further enhances proteolytic activation of SREBPs by stimulating ER to Golgi transport of Scap/SREBP. When SREBPs reach the nucleus, they activate transcription, causing increased cholesterol synthesis. Inasmuch as Insig-1 is also a target gene of SREBPs (Yabe et al. 2002; Horton et al. 2003), transcription of its mRNA is also stimulated (Fig. 2). SREBPs will continue to be sent to the nucleus until two criteria have been met: (1) the synthesis of Insig-1 mRNA has been increased sufficiently to allow new Insig-1 molecules to be made; and (2) sufficient cholesterol has been produced in order for newly synthesized Insig-1 to bind Scap thereby stabilizing Insig-1 and preventing incorporation of the Scap/SREBP complex into COP-II-coated vesicles.

Unlike Insig-1, Insig-2 is not a transcriptional target of SREBPs (Yabe et al. 2002). The protein also has a long half-life that is not regulated by sterols (Lee et al. 2006a). In cultured cells like CHO cells, the amount of Insig-2 is so low as not to interfere with the convergent regulatory scheme mediated by Insig-1 (Sever...
et al. 2004). However, in liver Insig-2 may play an important role in regulating the SREBP pathway. The role of Insig-2 in controlling hepatic lipid homeostasis will be discussed in detail below.

Regulation of SREBP-1 by Fatty Acids

SREBP-1 is more active to drive genes involved in fatty acid synthesis than those participated in cholesterol synthesis (Pai et al. 1998; Horton et al. 2003). Thus, SREBP-1 is also subjected to feedback inhibition by fatty acids. Polyunsaturated fatty acids (PUFA) inhibit transcription of SREBP-1 but not SREBP-2 (Ou et al. 2001). This is because transcription of SREBP-1 is activated by liver X receptors (LXRs) (Repa et al. 2000a; DeBose-Boyd et al. 2001), nuclear receptors that are antagonized by PUFA (Ou et al. 2001). In mice, PUFA inhibits transcription of the SREBP-1c, but not of SREBP-1a, owing to the presence of the LXR response element in the promoter of the SREBP-1c gene (Repa et al. 2000a). This is not the case in human cells in which the LXR response element is found in the promoter regions of both SREBP-1a and SREBP-1c. As a result, transcription of SREBP-1a is also inhibited by PUFA in human cells (Hannah et al. 2001).

Unsaturated fatty acids also inhibit proteolytic activation of SREBP-1 (Hannah et al. 2001). This activity is not limited to PUFA; mono-unsaturated fatty acids such as oleate inhibit SREBP processing as well. In contrast, saturated fatty acids are unable to suppress proteolytic activation of SREBP-1. Unsaturated fatty acids inhibit SREBP-1 cleavage by blocking the proteasomal degradation of Insig-1 (Lee et al. 2008). The excess Insig-1 has a more profound effect in blocking cleavage of SREBP-1 than that of SREBP-2 because more Insig-1 is required to inhibit proteolytic activation of SREBP-1 (Engelking et al. 2005; Lee et al. 2008). Because unsaturated fatty acids inhibit SREBP-1 cleavage by increasing the amount of Insig-1 protein, this inhibition is not independent of sterols, which are required for Insig-1 to bind Scap. Rather, by increasing the amount of Insig-1, unsaturated fatty acids make SREBP-1 more sensitive to the inhibitory effects of sterols (Lee et al. 2008).

Remarkably, unsaturated fatty acids and sterols inhibit Insig-1 degradation by different mechanisms. In sterol- and fatty acid-depleted cells, Insig-1 binds to gp78, a membrane-bound E3 ubiquitin ligase that attaches polyubiquitin chains to Insig-1 (Fig. 3) (Lee et al. 2006b). Insig-1 also binds to Ubxd8, a protein that recruits p97 complex to Insig-1 through its bridging interaction with both proteins (Fig. 3) (Lee et al. 2008). Ubiquitination of Insig-1 and recruitment of p97 to the protein lead to recognition and subsequent degradation of Insig-1 by proteasomes (Fig. 3) (Ikeda et al. 2009). Sterols cause Insig-1 to bind to Scap, and this precludes the binding of gp78, thereby inhibiting ubiquitination of Insig-1 (Fig. 3) (Lee et al. 2008). In contrast, sterols do not inhibit binding of the Ubxd8/p97 complex to Insig-1 (Lee et al. 2006b), as this interaction does not require ubiquitination of Insig-1 (Fig. 3) (Ikeda et al. 2009). Unsaturated fatty acids do not block this ubiquitination, but they prevent the recruitment of p97 to Insig-1 by blocking the interaction between Ubxd8 and Insig-1 (Fig. 3) (Lee et al. 2008). Inasmuch as ubiquitination and recruitment of p97 to Insig-1 is required for the protein to be recognized by proteasomes, either sterols or unsaturated fatty acids can block the degradation pathway. Thus, the regulated degradation of Insig-1 outlined in Figure 3 plays an important role in feedback inhibition in synthesis of cholesterol and fatty acids.

REGULATION OF THE SREBP PATHWAY IN THE LIVER

In mammals, the liver plays a major role in metabolism; the organ is one of the most active sites of cholesterol and fatty acid synthesis in the body. Consistent with studies in cultured cells, in vivo studies reveal that the SREBP pathway drives expression of a genetic program in the liver that leads to enhanced synthesis and uptake of cholesterol, fatty acids, triglycerides, and phospholipids. In this section, we review the role of individual SREBP isoforms
(SREBP-1a, -1c, and -2) and their membrane protein regulators (Scap and Insigs) in control of lipid synthesis in the liver. These roles were elucidated through the analysis of genetically manipulated mice in which the SREBP pathway was either activated or inactivated.

**Animal Models in which the SREBP Pathway is Activated**

The three SREBP isoforms are produced in culture cells as well as in the liver of animals, but at different ratios. In nonhepatic cells, the
SREBP-1a transcript is much more abundant than the SREBP-1c transcript (Shimomura et al. 1997). The SREBP-1c transcript predominates in the liver; its level can be up to 10-fold more abundant than that of the SREBP-1a transcript in the organ. The SREBP-2 transcript is present in all cells and tissues at a relatively constant level. To determine the function of the individual SREBP isoforms in the liver, transgenic mice overexpressing SREBPs that are truncated prior to the first transmembrane domain were generated. These proteins, designated nuclear SREBPs (nSREBPs), are synthesized in the cytosol rather than on ER membranes. As a result, they constitutively migrate to the nucleus and activate gene transcription without a requirement for proteolysis. Notably, nSREBPs are immune to feedback regulation by sterols.

Overexpression of nSREBP-1a had dramatic consequences on lipid metabolism in the liver (Shimano et al. 1996). Transgenic nSREBP-1a mice presented markedly elevated levels of mRNAs encoding genes required for cholesterol and fatty acid synthesis. As a result, the cholesterol and fatty acid synthetic rates were increased five-fold and 20-fold, respectively, which led to the progressive development of an enlarged liver filled with cholesterol and triglycerides. The preference of fatty acid synthesis in favor of cholesterol synthesis was preserved in nSREBP-1c transgenic mice; however, the effect was more pronounced (Shimano et al. 1997a). The livers of these animals overaccumulated triglycerides, but showed no increase in cholesterol. Consistent with this observation, mRNAs for hepatic fatty acid biosynthetic enzymes and fatty acid synthetic rates are elevated about fourfold, whereas rates of cholesterol synthesis and expression of cholesterol biosynthetic genes were unchanged (Shimano et al. 1997a). In contrast to results in nSREBP-1 transgenic livers, hepatic overexpression of nSREBP-2 resulted in preferential activation of cholesterol synthesis (20-fold) over fatty acid synthesis (4-fold) (Horton et al. 1998).

Transgenic mice that express a mutant version of Scap in the liver containing an asparagine substitution for aspartic acid-443 (D443N) in the sterol-sensing domain represents another animal model in which the SREBP pathway is activated (Korn et al. 1998). In cultured cells, the D443N mutation in Scap abolishes its binding to Insigs, which renders the protein refractory to sterol-mediated ER retention (Hua et al. 1996b; Yang et al. 2002). Thus, D443N Scap continues to facilitate transport-dependent activation of SREBPs in the presence of sterols and cells expressing the mutant protein overproduce cholesterol. Similarly, transgenic mice expressing Scap D443N in the liver produce elevated levels of nSREBPs as compared to wild type controls (Korn et al. 1998). Correspondingly, expression of genes required for synthesis and uptake of cholesterol and fatty acids were increased and the livers accumulated large amounts of cholesterol and triglycerides. When subjected to a diet enriched in cholesterol, processing of SREBPs was markedly resistant to suppression, demonstrating an essential role for Scap as a sterol sensor in the liver (Korn et al. 1998).

The final animal model for SREBP activation was created through germline disruption of the Insig-2 gene and liver-specific disruption of the Insig-1 gene through Cre-mediated recombination (Engelking et al. 2005). On a normal chow diet, these mice (designated L-Insig-1<sup>/−/−</sup>; Insig-2<sup>/−/−</sup>) overaccumulate cholesterol and triglycerides in the liver, but levels of nSREBPs and their target genes were not reduced. Cholesterol feeding failed to inhibit SREBP processing, reduce expression of lipogenic genes, and block lipid synthesis in Insig-1<sup>/−</sup>-2 double knockout mice. Moreover, the level of HMG CoA reductase protein, the rate-limiting enzyme in cholesterol synthesis, was disproportionately elevated compared to its mRNA in the livers. This observation is consistent with studies in cultured cells showing that Insigs not only mediate sterol-mediated ER retention of Scap, but they also mediate sterol-accelerated degradation of HMG CoA reductase (Sever et al. 2003; Goldstein et al. 2006; DeBose-Boyd 2008). Like Scap, HMG CoA reductase contains a sterol-sensing domain within its NH<sub>2</sub>-terminal membrane attachment region that precedes a large cytosolic domain; the cytosolic domain of HMG CoA reductase exerts all enzymatic activity (Liscum et al.
1985; Roitelman et al. 1992). Accumulation of sterols causes Insigs to bind to the membrane domain of HMG CoA reductase, initiating a series of reactions that lead to the polyubiquitination of the enzyme and its subsequent degradation by proteasomes. Together, these observations highlight the importance of Insigs in the regulation of lipid synthesis in the liver.

Animal Models in which the SREBP Pathway is Inactivated

In addition to the five mouse models in which the SREBP pathway is activated in the liver, six models have been generated to achieve the opposite effect: Inactivation of the SREBP pathway in the liver through the elimination of genes encoding either SREBP, S1P, or Scap and transgenic overexpression of Insig-1.

Complete lethality was observed following germline deletion of the SREBP-2 gene in mice with mortality occurring at embryonic days 7–8 (Shimano et al. 1997b). Homozygous disruption of the SREBP-1 gene, which eliminated both the SREBP-1a and SREBP-1c transcripts, led to partial lethality; 15%–45% of the mice survive past embryonic day 11. The surviving SREBP-1 knockout mice appeared normal at birth and throughout adulthood. Their livers showed reduced synthesis of fatty acids, owing to reduced expression of fatty acid biosynthetic genes. To compensate for the loss of SREBP-1, livers of the knockout mice manifest elevated levels of SREBP-2 mRNA and protein leading to increased transcription of cholesterol biosynthetic genes and increased cholesterol synthesis. In contrast to SREBP-1 and SREBP-2 knockout mice, selective disruption of SREBP-1c did not cause embryonic lethality; the animals showed reduced expression of fatty acid biosynthetic genes and reduced fatty acid synthesis (Liang et al. 2002). In addition, the compensatory increase in SREBP-2 activity and cholesterol synthesis was also observed in SREBP-1c knockouts.

Studies of the SREBP-1 and SREBP-2 knockout mice indicate that germline elimination of all nSREBPs is an embryonic lethal event. To overcome this lethality, animals were produced in which the SREBP pathway is inactivated in the livers of adults through Cre-mediated recombination. The liver-specific disruption of the S1P and Scap genes led to the dramatic reduction in levels of nSREBPs (Matsuda et al. 2001; Yang et al. 2001). Consequently, expression of SREBP target genes and rates of cholesterol and fatty acid synthesis were markedly diminished (20%–30% of wild type controls). The S1P and Scap knockout mice appear relatively normal in contrast to the embryonic lethality associated with SREBP-1 and SREBP-2 deficient animals.

In cultured cells, overexpression of Insigs renders Scap-mediated processing of SREBPs much more sensitive to sterols (Yang et al. 2002). When overexpressed at high levels, Insig-1 blocks SREBP processing, even in the absence of sterols. Similarly, overexpression of Insig-1 in the mouse liver caused a modest decrease (40%–50%) in the amount of nSREBPs and increased sensitivity of SREBP processing to inhibition by dietary cholesterol (Engelking et al. 2004). Consistent with this, the expression of SREBP target genes and rates of lipid synthesis are decreased in Insig-1 transgenic animals.

Studies of the 11 lines of genetically manipulated mice described in this section highlight the individual roles of SREBP isoforms in hepatic lipid metabolism. The major SREBP-1 isoform in the mouse liver, SREBP-1c, preferentially activates transcription of genes required for fatty acid synthesis, whereas SREBP-2 preferentially activates genes for cholesterol synthesis. Notably, SREBP-1c is relatively weak in stimulating transcription of target genes as compared to SREBP-1a and SREBP-2. This is likely because of differences in the length of an acidic sequence at the NH₂-terminus of the proteins that mediates transcriptional activation. The transcriptional activation domain is longer in SREBP-1a and SREBP-2 than in SREBP-1c. The feedback regulation of SREBP processing in the liver, much like the situation in cultured cells, is achieved through the sterol-induced binding of the sterol-sensing domain of Scap to Insigs, which traps the Scap/SREBP complex in the ER. These observations indicate that
general mechanisms that regulate SREBP processing operate similarly in the livers of mice as they do in cultured cells.

Transcriptional Regulation of the SREBP Pathway

In addition to elaborate control at the posttranslational level (ER to Golgi transport and proteolysis of SREBPs and proteasomal degradation of Insig-1 and HMG CoA reductase); the SREBP pathway is also subject to transcriptional regulation. Although posttranslational regulation of the SREBP pathway occurs in both cultured cells and livers of whole animals, transcriptional regulation is more evident in the liver.

At least three mechanisms operate in the liver to control transcription of SREBP genes. The first mechanism involves feed-forward transcriptional regulation of the SREBP-1c and SREBP-2 genes, which is mediated by sterol response elements (SREs) present in the promoter/enhancer region of each gene (Sato et al. 1996; Amemiya-Kudo et al. 2000). The SRE maintains the basal expression of the SREBP-1c gene in the liver (Fig. 4) (Chen et al. 2004). The feed-forward transcriptional control explains increased levels of SREBP mRNAs observed in nSREBP transgenic animals and decreased levels of the mRNAs in S1P- and Scap-deficient animals (Matsuda et al. 2001; Yang et al. 2001). In the second mechanism, LXRα and LXRβ, nuclear receptors that heterodimerize with retinoic X receptors and become activated by a variety of sterols such as oxysterols (Repa et al. 2000), selectively regulate the expression of the SREBP-1c gene (Repa et al. 2000; DeBose-Boyd et al. 2001; Liang et al. 2002). In LXRα- and LXRβ-deficient mice, expression of SREBP-1c and fatty acid biosynthetic genes are reduced and do not become up-regulated by synthetic LXR agonists (Repa et al. 2000). Similarly, fatty acid biosynthetic genes are not up-regulated by LXR agonists in SREBP-1c knockout mice (Liang et al. 2002). LXR-mediated regulation of SREBP-1c allows induction of fatty acid synthesis under conditions of sterol overload, which may have important implications for intracellular storage of esterified cholesterol.

The third mechanism for transcriptional regulation is also selective for the SREBP-1c gene. A key action of the hormone insulin is to stimulate synthesis of fatty acids in the liver. Transcription of the SREBP-1c gene in the livers of mice is reduced following fasting, which suppresses insulin levels, and elevated following refeeding, which restores insulin (Horton et al. 1998). A similar response pattern is observed for mRNAs encoding SREBP-1c target genes. Importantly, elimination of the SREBP-1c gene abolishes insulin-induced activation of fatty acid biosynthetic genes (Liang et al. 2002). Although the exact mechanism through which insulin augments transcription of the SREBP-1c gene is not known, the reaction appears to

Figure 4. Regulation of SREBP-1c expression in the liver. The promoter of SREBP-1c contains two LXR-response elements (LXRE) and a SRE. Nuclear SREBPs bind SRE to maintain basal transcription of SREBP-1c. Insulin stimulates the activity of LXR, which binds LXRE to activate transcription of SREBP-1c.
require the action of LXR and SREBP itself, thereby creating a feed forward stimulation (Fig. 4) (Chen et al. 2004). The livers of Scap knockout mice or Insig-1 transgenic mice show a marked decrease in insulin-mediated stimulation of fatty acid biosynthetic genes that normally occurs in wild type animals following the fasting/refeeding regimen (Matsuda et al. 2001; Engelking et al. 2004). Thus, proteolytic activation of SREBP-1c appears to mediate the action of insulin on fatty acid synthesis in the liver.

Insulin also has a major effect on the expression on Insigs in the liver. Two transcripts are derived from the Insig-2 gene: the liver-specific transcript designated Insig-2a and the ubiquitous transcript designated Insig-2b (Yabe et al. 2003). Insig-2a differs from Insig-2b because of the utilization of an upstream promoter that produces a different 5' noncoding exon that splices into the same coding exon that initiates Insig-2b. The Insig-2a and Insig-2b transcripts encode the same protein. Insig-2b is expressed at very low levels in the liver, whereas Insig-2a is expressed at high levels in the liver, but only when insulin levels are low.

Reciprocal regulation of Insigs is observed in the livers of mice subjected to the fasting/refeeding protocol. In fasting mice when insulin levels are low, the SREBP-1c gene is not transcribed and nSREBP-1c is not produced. In addition, Insig-1 mRNA and protein levels are reduced and Insig-2 protein levels rise, owing to increased production of the Insig-2a transcript. When insulin levels rise after refeeding, Insig-2 mRNA, and protein rapidly disappears because of transcriptional repression. At the same time, insulin induces transcription of the SREBP-1c gene, nSREBP-1c activates the Insig-1 gene, and Insig-1 mRNA and protein levels are restored, effectively replacing Insig-2 with Insig-1. The significance of the reciprocal regulation of Insigs to the regulation of SREBP processing in the liver is still under investigation.

CONCLUSIONS AND PERSPECTIVES

As we have outlined in this article, the discovery of the SREBP pathway nearly 20 years ago has led to major advances in the understanding of molecular mechanisms that govern the synthesis and uptake of cholesterol and fatty acids. Despite these advances at both the cellular and whole-animal level, key questions remain. For example, what is the molecular basis for the interactions of cholesterol and oxysterols with the membrane domain of Scap and Insigs, respectively? What amino acid residues in these proteins mediate sterol binding? How do interactions with sterols trigger formation of the Scap-Insig complex? Answers to these questions can only be provided by detailed structural analysis of Scap and Insigs by X-ray crystallography. This is an especially challenging task considering the insolubility of sterols in aqueous solution and the requirement of detergents to solubilize the hydrophobic Scap and Insig proteins.

The other unresolved questions in the SREBP pathway pertain to the action of insulin on lipid metabolism through stimulation of SREBP-1c transcription and proteolytic activation. Recent studies have implicated a kinase complex designated the mammalian target of rapamycin complex 1 (mTORC1) in the insulin-mediated induction of SREBP-1c transcription (Li et al. 2010). Although the mechanism through which mTORC1 modulates SREBP-1c expression remains to be determined, the possibility exists that the kinase may activate SREBP-1c, LXR, or a coactivator that interacts with these transcription factors. Considering that SREBP-1c must be proteolytically activated to modulate target gene expression, an obvious question is whether insulin also stimulates cleavage of the protein. However, this requires the examination of transgenic animals expressing full-length SREBP-1c in the liver under transcriptional control of an insulin-independent, constitutive promoter.

REFERENCE


Amemiya-Kudo M, Shimano H, Yoshikawa T, Yahagi N, Hasty AH, Okazaki H, Tamura Y, Shionoiri E, Iizuka Y,
Regulation of Cholesterol and Fatty Acid Synthesis


Regulation of Cholesterol and Fatty Acid Synthesis

